97-15510. HIV and STD Intervention Research for Young Men in Prison  

  • [Federal Register Volume 62, Number 114 (Friday, June 13, 1997)]
    [Notices]
    [Pages 32340-32345]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 97-15510]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Centers for Disease Control and Prevention
    [Announcement 750]
    
    
    HIV and STD Intervention Research for Young Men in Prison
    
    Introduction
    
        The Centers for Disease Control and Prevention (CDC) announces the 
    availability of fiscal year (FY) 1997 funds for a cooperative agreement 
    program to stimulate the development of innovative science-based models 
    that assist local communities in the prevention of HIV/STD infection 
    and transmission among young men in prison who are ready to return to 
    their communities.
        CDC is committed to achieving the health promotion and disease 
    prevention objectives of ``Healthy People 2000,'' a national activity 
    to reduce morbidity and mortality and improve the quality of life. This 
    announcement is related to the priority area Human Immunodeficiency 
    Virus (HIV) Infection. (For ordering a copy of ``Healthy People 2000,'' 
    see the section Where to Obtain Additional Information.)
    
    [[Page 32341]]
    
    Authority
    
        This program is authorized under Sections 301 and 317(k)(2), of the 
    Public Health Service Act (42 U.S.C. 241 and 247b(k)(2) as amended.
    
    Smoke-Free Workplace
    
        CDC strongly encourages all recipients to provide a smoke-free 
    workplace and to promote the nonuse of all tobacco products, and Public 
    Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain 
    facilities that receive Federal funds in which education, library, day 
    care, health care, and early childhood development services are 
    provided to children.
    
    Eligible Applicants
    
        Applications may be submitted by public and private, nonprofit and 
    for-profit organizations, and governments and their agencies. Thus, 
    universities, colleges, research institutes, community-based 
    organizations, hospitals, other public and private organizations, State 
    and local health departments or their bona fide agents or 
    instrumentalities, federally recognized Indian tribal governments, 
    Indian tribes or Indian tribal organizations, and small, racial-ethnic 
    or women-owned businesses are eligible to apply.
    
    Availability of Funds
    
        Approximately $1,200,000 is available in FY 1997 to fund four 
    awards. It is expected that the average award will range from $275,000 
    to $325,000. The awards are expected to begin on or about September 30, 
    1997, and will be made for a 12-month budget period within a project 
    period of up to five years. Continuation awards will be made on the 
    basis of satisfactory progress and the availability of funds. Funding 
    estimates may vary and are subject to change. Applications requesting 
    greater than $325,000 will not be considered for funding.
    
    Use of Funds
    
    Restrictions on Lobbying
    
        Applicants should be aware of restrictions on the use of HHS funds 
    for lobbying of Federal or State legislative bodies. Under the 
    provisions of 31 U.S.C. Section 1352 (which has been in effect since 
    December 23, 1989), recipients (and their subtier contractors) are 
    prohibited from using appropriated Federal funds (other than profits 
    from a Federal contract) for lobbying Congress or any Federal agency in 
    connection with the award of a particular contract, grant, cooperative 
    agreement, or loan. This includes grants/cooperative agreements that, 
    in whole or in part, involve conferences for which Federal funds cannot 
    be used directly or indirectly to encourage participants to lobby or to 
    instruct participants on how to lobby.
        In addition, the FY 1997 HHS Appropriations Act, which became 
    effective October 1, 1996, expressly prohibits the use of 1997 
    appropriated funds for indirect or ``grass roots'' lobbying efforts 
    that are designed to support or defeat legislation pending before State 
    legislatures. This new law, Section 503 of Pub. L. No. 104-208, 
    provides as follows:
    
        Sec. 503(a) No part of any appropriation contained in this Act 
    shall be used, other than for normal and recognized executive-
    legislative relationships, for publicity or propaganda purposes, for 
    the preparation, distribution, or use of any kit, pamphlet, booklet, 
    publication, radio, television, or video presentation designed to 
    support or defeat legislation pending before the Congress, * * * 
    except in presentation to the Congress or any State legislative body 
    itself.
        (b) No part of any appropriation contained in this Act shall be 
    used to pay the salary or expenses of any grant or contract 
    recipient, or agent acting for such recipient, related to any 
    activity designed to influence legislation or appropriations pending 
    before the Congress or any State legislature.
    
        Department of Labor, Health and Human Services, and Education, and 
    Related Agencies Appropriations Act, 1997, as enacted by the Omnibus 
    Consolidated Appropriations Act, 1997, Division A, Title I, Section 
    101(e), Pub. L. No. 104-208 (September 30, 1996).
    
    Background: HIV/AIDS in the U.S. Prison Population
    
        There are over 6 million adults or 2.6% of the total adult U.S. 
    population under some form of correctional custody on any given day. A 
    recent national survey of routine STD testing in correctional 
    facilities found positivity rates for syphilis among inmates that range 
    from 0% to 17% and positivity rates for gonorrhea ranging from 0% to 
    32.5%. The prevalence of AIDS among inmates is 5.2 per thousand, or 
    nearly six times the total U.S. adult population rate of 0.9 per 
    thousand. HIV seroprevalence rates among prison populations vary by 
    region, ranging from 2% to as high as 26%. Approximately 93% of all 
    inmate deaths from AIDS are among men. Compared to men in the general 
    population, men entering prisons typically have substantially higher 
    rates of STDs, HIV infection and risk behaviors for HIV infection such 
    as injecting drug use, sexual contact with injecting drug using 
    partners, homemade tattoos and other blood exposures.
        In the United States, injection drug users represent about 25% of 
    all AIDS cases and 42% of cases acquired through heterosexual 
    transmission have been attributed to sexual contact with an injection 
    drug user. In 1991 there were over 177,750 injection drug users in 
    State prisons alone. Nationwide, approximately 70% of inmates have a 
    history of injection drug use. It is obvious that prisons are important 
    settings for reaching men who are at increased risk for HIV infection 
    with risk reduction information.
        Unfortunately, a recent survey of prison administrators found that 
    from 1992 to 1994, the number of prisons that provided instructor-led 
    HIV educational programs for inmates declined. In addition, the number 
    of prison systems that made HIV education available to inmates through 
    videos and other audiovisual materials also declined. In spite of the 
    tremendous increase in the numbers of young men who are incarcerated, 
    very few prevention programs have been specifically designed and 
    evaluated for young men in prison.
        Prison populations provide a means of accessing large numbers of 
    young men who have engaged in high risk behaviors and are likely to do 
    so again upon their release from prison. Without support and assistance 
    in making the transition from prison life to a stable life back in 
    their communities, it is probable that inmates may relapse to drug use 
    and risky sexual behaviors. Young male inmates may be more readily 
    encouraged to alter their risky behaviors compared to older inmates who 
    are more likely to have longer histories of risky behavior and because 
    of longer sentences, will have less opportunity to practice risk 
    reduction behaviors. According to national figures most inmates remain 
    incarcerated for an average of 18 months. An intervention that begins 
    to address HIV and STD prevention immediately prior to young men's 
    release from prison and that continues to provide ongoing intervention 
    and support for behavior change following release is a much needed 
    model. Therefore, it is vital that an HIV and STD prevention 
    intervention for this population be designed, tested and evaluated in 
    order to assist communities in addressing the unmet risk-reduction 
    needs of this population.
    
    Purpose
    
        The objective of this announcement is to advance the field of HIV-
    prevention science so that local communities will have available to 
    them a range of scientifically sound intervention
    
    [[Page 32342]]
    
    strategies to use in their prevention programs for young men (ages 18 
    to 25) in prisons. To reach this goal it is essential that programs 
    work with communities to accomplish this research so that interventions 
    will be feasible and acceptable to the community. A critical goal of 
    this research is to connect local researchers with community and 
    prison-based prevention programs in order to build the capacity of 
    local communities to sustain intervention work after the research is 
    completed.
        Behavioral intervention research of this type often involves three 
    distinct phases. The first phase involves the collection of qualitative 
    and quantitative data that leads to a better understanding of the study 
    population, its risk-related practices, as well as barriers and 
    facilitators to the adoption and maintenance of reduced behavioral risk 
    practices. In the second phase, this information is used to develop an 
    intervention strategy, which is then piloted on a small scale to 
    determine the feasibility and acceptability of the intervention. In the 
    third phase, a refined intervention model is tested to evaluate its 
    ability to influence risk-related practices and attitudes. This 
    announcement is designed to support local research efforts in each of 
    these three phases.
        Facilitating participation in the development of a common cross-
    site research protocol is an essential objective of this announcement. 
    The collection of comparable data across sites provides a number of 
    significant advantages with regard to advancing the field of 
    intervention research. First, the prevalence of risk-related practices 
    and beliefs can be systematically evaluated across different 
    populations and regions of the country. Second, collection of 
    comparable process and outcome evaluation data allows the relative 
    effectiveness of different intervention strategies to be assessed. 
    Third, the inability of a single-site project to recruit sufficient 
    participants to reliably measure biological outcome measures such as 
    STD and HIV incidence can be overcome with a multi-site effort.
    
    Program Requirements
    
        To achieve the purpose of this project, the recipient will be 
    responsible for the activities under A. (Recipient Activities). The CDC 
    will provide assistance with the activities listed under B. (CDC 
    Activities).
    
    A. Recipient Activities
    
        To achieve the objectives of this announcement, it is recommended 
    that each cooperative agreement recipient form a multi-disciplinary 
    research team, led by behavioral and social scientists skilled in 
    conducting intervention research. This team will guide the 
    implementation of research and intervention protocols that will be 
    developed collaboratively by the cooperative agreement recipients. To 
    ensure the feasibility and acceptability of the intervention strategy 
    in the local community, the research team should develop formal 
    mechanisms to solicit on-going input from relevant stakeholders such as 
    inmate representatives, corrections staff, staff from participating 
    community based organizations, and data analysts.
        The multi-disciplinary research team will:
        1. Collaborate with other cooperative agreement recipients in 
    developing a common research protocol.
        2. Following the common study protocol, conduct formative research 
    to describe the risk behaviors of the study population as well as 
    psychosocial and other factors that influence their HIV and STD risk 
    behavior.
        3. Following the common study protocol, pilot test and rigorously 
    evaluate the impact of the intervention developed earlier in the 
    project.
        4. Collaborate with other cooperative agreement recipients in data 
    analysis and dissemination of research findings so that they are 
    accessible and usable to local communities and other researchers.
        Given the collaborative nature of this effort, it is anticipated 
    that key staff from each cooperative agreement recipient's agency will 
    attend four meetings of all the cooperative agreement recipients each 
    year and participate in regular telephone conference calls throughout 
    the duration of the project.
    
    B. CDC Activities
    
        CDC staff will collaborate with cooperative agreement recipients, 
    providing guidance and coordination throughout the duration of the 
    project. Activities that will be conducted by the CDC include:
        1. Participate in developing research protocols including data 
    collection procedures and instruments;
        2. Assist in the scientific and operational conduct of the research 
    project to ensure that HIV prevention science and community needs are 
    met;
        3. Coordinate cross-site data aggregation and analyses to ensure 
    that HIV prevention science and community needs are met.
        4. Participate in the preparation of study results for publication.
        It is anticipated that within the first 3 months of the cooperative 
    agreement, all recipients will complete the common research protocol 
    and in the next 3 months pilot test its components. Around the 18th 
    month of the project, recipients will agree on the essential components 
    of the common intervention protocol for pilot testing. Following the 
    pilot testing, the feasibility of implementing a rigorous research 
    evaluation of the intervention will be assessed. Intervention studies 
    that are scientifically rigorous, acceptable to the study population, 
    and likely to lead to reductions in HIV and STD risk will move ahead to 
    the intervention trial phase.
    
    Technical Reporting Requirements
    
        An original and two copies of semiannual progress reports are 
    required. Time lines for the quarterly reports will be established at 
    the time of award. Final financial status and performance reports are 
    required no later than 90 days after the end of the project period. All 
    reports are to be submitted to the Grants Management Branch, 
    Procurement and Grants Office, CDC.
    
    Application Content
    
        Applications must be developed in accordance with PHS Form 398 (OMB 
    Number 0925-0001), information contained in the program announcement 
    and the instructions provided below. Applicants are required to submit 
    an original and two copies of the application. All page limits 
    specified in the PHS 398 application kit must be adhered to with the 
    exception that sections a-d of the Research Plan must not exceed 15 
    pages in length. Material in appendices should be one-sided only.
        The following information should be addressed within the Research 
    Plan section of the application narrative:
    
    1. Population and Facility
    
        a. Demonstrate familiarity with HIV/STD issues faced by young men 
    making the transition back to their communities and identify the 
    factors associated with the transmission of HIV/STD within the proposed 
    study population;
        b. Describe the prison facility and the characteristics of the 
    participants who will be recruited, including the total number of 
    incarcerated young men aged 18-25. Describe with regard to men ages 18 
    to 25: overall number of inmates released from prison each month for 
    the past year, number of men on parole, number of violent and non-
    violent inmates, rates of recidivism, race/ethnicity data, number of 
    men tested for
    
    [[Page 32343]]
    
    HIV, the percentage of young men who are HIV positive, the percentage 
    of new inmates who test positive for an STD and the percentage that are 
    diagnosed with an STD during the period of incarceration;
        c. Describe the plans to involve young men, correctional staff, and 
    service providers in the development of research and intervention 
    activities;
        d. Include procedures for obtaining informed consent, Institutional 
    Review Board (IRB) clearance, and maintaining participant 
    confidentiality;
        e. Describe ongoing HIV/STD education and prevention activities 
    with this population within the prison facility and in the community;
        f. Describe linkages between the prison facility, local community 
    health department resources, and community based organizations. Include 
    a list with descriptions of referral organizations and their services. 
    Also enclose letters of support from each organization that are 
    specific in identifying the services that they will provide;
        g. Include a letter of support from the Warden and the Medical 
    Director of the participating correctional facilities that states they 
    will participate in the project and support the research and 
    intervention activities.
    
    2. Formative Research Plan
    
        a. Describe the plan to conduct formative research. Discuss what 
    factors will be examined and the rationale for studying these factors 
    based on the scientific literature;
        b. Provide a statement of the willingness of the research team to 
    work collaboratively with the other cooperative agreement recipients in 
    developing a common research protocol and to disseminate study 
    findings;
        c. Describe plans for following participants for a minimum of six 
    months following their release from prison; and,
        d. Describe the methods for collecting and analyzing qualitative 
    and quantitative data.
    
    3. Research and Intervention Capability of Applicant
    
        a. Describe the professional training and relevant experience of 
    the research team;
        b. Provide descriptions and major findings of HIV-related research 
    and behavioral intervention studies that have been conducted by members 
    of the research team;
        c. Include a table of current and previous relevant research 
    projects, their principal investigators, status, sources and levels of 
    funding; and
        d. Include in the appendix, the curriculum vitae for key staff 
    members as well as memoranda of agreement that document activities to 
    be performed by any external experts, consultants, or collaborating 
    agencies under the cooperative agreement.
    
    4. Staffing, Facilities, and Time Line
    
        a. Explain the proposed staffing structure (positions/titles), the 
    percentage of time each staff member commits to this study and other 
    projects, and the division of duties and responsibilities for the 
    project;
        b. Identify and describe the key roles of behavioral scientists and 
    other staff essential to the conduct and the completion of the project;
        c. Describe the duties and responsibilities of project personnel to 
    conduct project oversight and data management;
        d. Describe the existing facilities, equipment, computer software, 
    data processing capacity, and describe the procedures to ensure the 
    security of research data; and,
        e. Provide a time line for the completion of the proposed research.
    
    5. Budget
    
        Provide a detailed, line-item budget for the project and a budget 
    narrative that justifies each line-item.
    
    Evaluation Criteria
    
        Applications that meet the eligibility requirements will be 
    reviewed and evaluated according to the following criteria:
    
    1. Familiarity With HIV/AIDS and STD Risk Behaviors of Young Men. (20 
    Points)
    
        a. Extent of applicant's knowledge of HIV/STD issues faced by young 
    men ready for release to their communities and familiarity with the 
    relevant research;
        b. Thoroughness of the description of risk behaviors that are 
    associated with the transmission of HIV/STD in the proposed study 
    population;
        c. Inclusion of a description of the facility and the ability to 
    show the availability of sufficient numbers of participants to achieve 
    the study objectives, including the total number of incarcerated young 
    men aged 18-25, described in terms of the following: overall number of 
    inmates released each month for the past year, number of men on parole, 
    number of violent and non-violent inmates, rates of recidivism, race/
    ethnicity data, number of men tested for HIV, the percentage that are 
    positive in the institution annually, the percentage of new inmates who 
    test positive for an STD and the percentage that are diagnosed with an 
    STD during the period of incarceration;
        d. Quality of the plan to involve young men, correctional staff, 
    and service providers in the development of research and intervention 
    activities;
        e. Adequacy of the procedures for obtaining informed consent, IRB 
    clearance and maintaining participant confidentiality;
        f. Documentation and coordination of any ongoing HIV/STD education 
    and prevention activities with this population within the prison 
    facility and in the community;
        g. Adequacy of the linkages with local community health department 
    resources, and community based organizations. Presence of list of 
    referral organizations and their services. Presence of letters of 
    support from each organization specifying the service that they will 
    provide; and,
        h. Inclusion of the letter of support from the Warden and the 
    Medical Director of the selected correctional facility stating their 
    willingness to participate in the project and to actively support the 
    research and intervention activities.
    
    2. Formative Research Plan (30 Points)
    
        a. Thoroughness of the applicant's understanding of the scientific 
    literature related to HIV/STD risk and risk reduction with the target 
    population;
        b. Quality of the plan to conduct formative research that will 
    yield information relevant to the development of HIV/STD risk reduction 
    interventions for young men who are ready for release;
        c. Presence of a statement showing the willingness of the research 
    team to work collaboratively with the CDC and the other cooperative 
    agreement recipients in developing a common research protocol and to 
    disseminate study findings;
        d. The proposed plan for the inclusion of racial and ethnic 
    minority populations for appropriate representation and the proposed 
    justification when representation is limited or absent;
        e. Adequacy of plans to test the feasibility of following 
    participants for six months following their release from prison; and,
        f. Quality of the methods described for collecting and analyzing 
    qualitative and quantitative data.
    
    3. Research and Intervention Capability (35 Points)
    
        a. Quality of the professional training and relevant research 
    experience of the research team;
        b. Relevance and quality of HIV-related research and behavioral
    
    [[Page 32344]]
    
    intervention studies that have been conducted by members of the 
    research team;
        c. Inclusion of a table of current and previous relevant research 
    projects, their principal investigators, status, sources and levels of 
    funding; and,
        d. Completeness of requested materials in the appendix, the 
    curriculum vitae for key staff members as well as memoranda of 
    agreement that clearly and specifically document activities to be 
    performed by any external experts, consultants, or collaborating 
    agencies under the cooperative agreement.
    
    4. Staffing, Facilities, and Time Line (15 Points)
    
        a. Adequacy of the proposed staffing structure (positions/titles), 
    the percentage of time each staff member commits to this and other 
    projects, and the division of duties and responsibilities for the 
    project;
        b. Clarity and appropriateness of the key roles of behavioral 
    scientists and other staff essential to the conduct and the completion 
    of the project;
        c. Clarity of the described duties and responsibilities of project 
    personnel to conduct project oversight and data management;
        d. Adequacy of the existing facilities, equipment, computer 
    software, data processing capacity, and the procedures to ensure the 
    security of research data; and,
        e. Completeness and reasonableness of time line for the proposed 
    research.
    
    5. Budget (Not Scored)
    
        Extent to which the budget is reasonable, itemized, clearly 
    justified, and consistent with the intended use of the funds.
    
    Executive Order 12372 Review
    
        Applications are subject to Intergovernmental Review of Federal 
    Programs as governed by Executive Order (E.O.) 12372. E.O. 12372 sets 
    up a system for State and local government review of proposed Federal 
    assistance applications. Applicants (other than federally recognized 
    Indian tribal governments) should contact their State Single Point of 
    Contact (SPOC) as early as possible to alert them to the prospective 
    applications and receive any necessary instructions on the State 
    process. For proposed projects serving more than one State, the 
    applicant is advised to contact the SPOC for each affected State. A 
    current list of SPOCs is included in the application kit. If SPOCs have 
    any State process recommendations on applications submitted to CDC, 
    they should send them to Van Malone, Grants Management Officer, Grants 
    Management Branch, Procurement and Grants Office, Centers for Disease 
    Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 300, 
    Mailstop E15, Atlanta, GA 30305, no later than 30 days after the 
    application deadline. The granting agency does not guarantee to 
    ``accommodate or explain'' for State process recommendations it 
    receives after that date.
        Indian tribes are strongly encouraged to request tribal government 
    review of the proposed application. If tribal governments have any 
    tribal process recommendations on applications submitted to the CDC, 
    they should forward them to Van Malone, Grants Management Officer, 
    Grants Management Branch, Procurement and Grants Office, Centers for 
    Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., 
    Room 300, Mailstop E15, Atlanta, GA 30305. This should be done no later 
    than 30 days after the application deadline date. The granting agency 
    does not guarantee to ``accommodate or explain'' for tribal process 
    recommendations it receives after that date.
    
    Public Health System Reporting Requirements
    
        This program is subject to the Public Health System Reporting 
    Requirements. Under these requirements, all community-based 
    nongovernmental applicants must prepare and submit the items identified 
    below to the head of the appropriate State and/or local health 
    department agency(s) in the program area(s) that may be impacted by the 
    proposed project no later than the receipt date of the Federal 
    application. The appropriate State and/or local health agency is 
    determined by the applicant. The following information must be 
    provided:
        A. A copy of the face page of the application (SF 424).
        B. A summary of the project that should be titled ``Public Health 
    System Impact Statement'' (PHSIS), not exceed one page, and include the 
    following:
        1. A description of the population to be served
        2. A summary of the services to be provided; and,
        3. A description of the coordination plans with the appropriate 
    State and/or local health agencies.
        If the State and/or local health official should desire a copy of 
    the entire application, it may be obtained from the State Single Point 
    of Contact (SPOC) or directly from the applicant.
    
    Catalog of Federal Domestic Assistance Number
    
        The Catalog of Federal Domestic Assistance number is 93.941.
    
    Other Requirements
    
    Paperwork Reduction Act
    
        Projects that involve the collection of information from 10 or more 
    individuals and funded by the cooperative agreement will be subject to 
    review by the Office of Management and Budget (OMB) under the Paperwork 
    Reduction Act.
    
    Human Subjects
    
        If the proposed project involves research on human subjects, the 
    applicant must comply with the Department of Health and Human Services 
    Regulations, 45 CFR Part 46, regarding the protection of human 
    subjects. Assurance must be provided to demonstrate that the project 
    will be subject to initial and continuing review by an appropriate 
    institutional review committees. In addition to other applicable 
    committees, Indian Health Service (IHS) institutional review committees 
    also must review the project if any component of IHS will be involved 
    or will support the research. If any American Indian community is 
    involved, its tribal government must also approve that portion of the 
    project applicable to it. The applicant will be responsible for 
    providing assurance in accordance with the appropriate guidelines and 
    form provided in the application kit.
    
    Racial and Ethnic Minorities
    
        It is the policy of the Centers for Disease Control and Prevention 
    (CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) 
    to ensure that individuals of the various racial and ethnic groups will 
    be included in CDC/ATSDR-supported research projects involving human 
    subjects, whenever feasible and appropriate. Racial and ethnic groups 
    are those defined in OMB Directive No. 15 and include American Indian, 
    Alaskan Native, Asian, Pacific Islander, Black and Hispanic. Applicants 
    shall ensure that racial and ethnic minority populations are 
    appropriately represented in applications for research involving human 
    subjects. Where clear and compelling rationale exist that inclusion is 
    inappropriate or not feasible, this situation must be explained as part 
    of the application. This policy does not apply to research studies when 
    the investigator cannot control the race, ethnicity and/or sex of 
    subjects. Further guidance to this policy
    
    [[Page 32345]]
    
    is contained in the Federal Register, Vol. 60, No. 179, pages 47947-
    47951, and dated September 15, 1995.
    
    HIV/AIDS Requirements
    
        Recipients must comply with the document entitled Content of AIDS-
    Related Written Materials, Pictorials, Audiovisuals, Questionnaires, 
    Survey Instruments, and Educational Sessions (June 1992), a copy of 
    which is included in the application kit. At least one member of the 
    program review panel must be an employee (or designated representative) 
    of the health department consistent with the Content guidelines. The 
    names of the review panel members must be listed on the Assurance of 
    Compliance for CDC 0.1113, which is also included in the application 
    kit. The recipient must submit, an attachment to the quarterly 
    summaries, the program review panel's report that all material have 
    been reviewed and approved.
    
    Application Submission and Deadlines
    
    1. Preapplication Letter of Intent
    
        A non-binding letter of intent-to-apply is required from potential 
    applicants. An original and two copies of the letter should be 
    submitted to the Grants Management Branch, CDC (see ``Applications'' 
    for the address). It should be postmarked no later than July 14, 1997. 
    The letter should identify the announcement number, name of principal 
    investigator, and specify the activity(ies) to be addressed by the 
    proposed project. The letter of intent does not influence review or 
    funding decisions, but it will enable CDC to plan the review more 
    efficiently, and will ensure that each applicant receives timely and 
    relevant information prior to application submission.
    
    2. Applications
    
        An original and two copies of the application PHS Form 398 (OMB 
    Number 0925-0001) must be submitted to Van Malone, Grants Management 
    Officer, Grants Management Branch, Procurement and Grants Office, 
    Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry 
    Road, NE., Room 300, Mailstop E-15, Atlanta, GA 30305, on or before 
    August 7, 1997.
    
    3. Deadlines
    
        a. Applications shall be considered as meeting the deadline if they 
    are either:
        (1) Received on or before the deadline date; or,
        (2) Sent on or before the deadline date and received in time for 
    submission to the objective review group. (Applicants must request a 
    legibly dated U.S. Postal Service postmark or obtain a legibly dated 
    receipt from a commercial carrier or the U.S. Postal Service. Private 
    metered postmarks shall not be acceptable as proof of timely mailing.)
        b. Applications that do not meet the criteria in 3.a.(1) or 3.a.(2) 
    above are considered late applications. Late applications will not be 
    considered in the current competition and will be returned to the 
    applicant.
    
    Where To Obtain Additional Information
    
        A complete program description, information on application 
    procedures, an application package and business management technical 
    assistance may be obtained from Van Malone, Grants Management Officer, 
    Grants Management Branch, Procurement and Grants Office, Centers for 
    Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., 
    Room 300, Mailstop E-15, Atlanta, GA 30305, telephone (404) 842-6575, 
    email: vxm7@cdc.gov.
        Programmatic technical assistance may be obtained from Robert 
    Kohmescher, Division of HIV/AIDS Prevention, National Center for HIV/
    STD/TB Prevention, Centers for Disease Control and Prevention (CDC), 
    1600 Clifton Road, NE., Mailstop E-44, Atlanta, GA 30333, telephone 
    (404) 639-8302, email: rnk1@cdc.gov.
        Please refer to Announcement 750 when requesting information and 
    submitting an application. Potential applicants may obtain a copy of 
    ``Healthy People 2000,'' (Full Report, Stock No. 017-001-00474-0) or 
    ``Healthy People 2000,'' (Summary Report, Stock No. 017-001-00473-1) 
    referenced in the Introduction, through the Superintendent of 
    Documents, Government Printing Office, Washington, DC 20402-9325, 
    telephone (202) 512-1800.
    
    Internet Home Page
    
        The announcement will be available on one of two Internet sites on 
    the publication date: CDC's home page at http://www.cdc.gov, or at the 
    Government Printing Office home page (including free access to the 
    Federal Register) at http://www.access.gpo.gov.
    
        Dated: June 9, 1997.
    Joseph R. Carter,
    Acting Associate Director for Management and Operations, Centers for 
    Disease Control and Prevention (CDC).
    [FR Doc. 97-15510 Filed 6-12-97; 8:45 am]
    BILLING CODE 4163-18-P
    
    
    

Document Information

Published:
06/13/1997
Department:
Centers for Disease Control and Prevention
Entry Type:
Notice
Document Number:
97-15510
Dates:
CDC's home page at http://www.cdc.gov, or at the Government Printing Office home page (including free access to the Federal Register) at http://www.access.gpo.gov.
Pages:
32340-32345 (6 pages)
Docket Numbers:
Announcement 750
PDF File:
97-15510.pdf